Ambrisentan Tablet, Film Coated
Product Images NDC 60505-4552

9 FDA label images from Apotex Corp. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ambrisentan (NDC 60505-4552). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl-5mg30s.jpg (Lbl 5mg30s)

Lbl-5mg30s.jpg (Lbl 5mg30s)
Packaging label for Ambrisentan Tablets 5 mg, film-coated oral tablets supplied in a container of 30 tablets. The label includes storage instructions, dispensing precautions, and manufacturer information for Apotex Corp. The NDC code 60505-4552-3 is displayed along with a barcode.*
FDA Label Image

Ctn-lbl-5mg10s.jpg (Ctn Lbl 5mg10s)

Ctn-lbl-5mg10s.jpg (Ctn Lbl 5mg10s)
Ambrisentan Tablets 5 mg film-coated oral tablets packaging label by Apotex Corp. The label states the package contains 10 unit-dose tablets. The NDC is 60505-4552-0. It includes instructions for pharmacists to dispense the enclosed Medication Guide and marks the product as prescription only.*
FDA Label Image

Lbl-10mg30s.jpg (Lbl 10mg30s)

Lbl-10mg30s.jpg (Lbl 10mg30s)
Ambrisentan Tablets 10 mg film-coated oral tablets in a 30-tablet package. The label includes the NDC 60505-4553-3, storage instructions, and dispensing information. Manufactured by Apotex Inc., Toronto, and labeled by Apotex Corp., Weston, Florida. The label is marked Rx only.*
FDA Label Image

Ctn-lbl-10mg10s.jpg (Ctn Lbl 10mg10s)

Ctn-lbl-10mg10s.jpg (Ctn Lbl 10mg10s)
Packaging label for Ambrisentan Tablets 10 mg by Apotex Corp. The label indicates the product contains 10 mg film-coated tablets in a 10-count unit-dose package. It includes a pharmacist instruction to dispense the enclosed Medication Guide, displays the NDC number 60505-4553-0, and notes the product is for prescription use only.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Ambrisentan, showing its molecular framework including aromatic rings, methyl, methoxy, carboxyl groups, and nitrogen-containing heterocyclic rings.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A chart illustrating the pharmacokinetic interactions between ambrisentan and various drugs. It shows fold changes and 90% confidence intervals for Cmax and AUC relative to ambrisentan alone for cyclosporine, mycophenolate mofetil, ketoconazole, omeprazole, rifampin, ritonavir, tacrolimus, and warfarin, with recommendations on dose adjustments.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A forest plot showing fold change and 90% confidence intervals for pharmacokinetic (PK) parameters Cmax, AUC, Emax, and AUEC of various interacting drugs including Cyclosporine, Digoxin, Ethinylestradiol, Norethindrone, Mycophenolic acid, Ritonavir, and Warfarin (S- and R-enantiomers). The x-axis represents change relative to interacting drug alone, and the recommendation column indicates no dose adjustment for all listed drugs.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
Two line graphs labeled ARIES-1 and ARIES-2 show meters moved over time (Baseline, Week 4, Week 8, Week 12) comparing placebo and different Ambrisentan doses (5 mg and 10 mg for ARIES-1; 2.5 mg and 5 mg for ARIES-2). Both graphs depict distance increasing with higher doses, while placebo decreases over time.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
Two Kaplan-Meier survival curves from studies ARIES-1 and ARIES-2 showing event-free percentages over 12 weeks. Each graph compares Ambrisentan (solid line) to placebo (dotted line) with time in weeks on the x-axis and event-free percentage on the y-axis. Numbers at risk are listed at intervals. ARIES-1 ends with 97% event-free for Ambrisentan and 89% for placebo, p=0.030. ARIES-2 ends with 94% event-free for Ambrisentan and 79% for placebo, p=0.005.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.